To investigate the efficacy of fasudil in the treatment of coronary slow flow and its effect on hs-CRP、MCP-1、ET-1 and ROCKⅠ.

Eighty two patients with CSF and normal coronary angiography were selected. Patients were randomly divided into conventional treatment group and fasudil group, 41 cases in each group. Patients in conventional treatment group were given conventional treatment (aspirin, nitrates and Simvastatin), while patients in the fasudil group were given fasudil on the basis of conventional treatment. The frequency of angina pectoris, ECG, TIMI, the plasma levels of hs-CRP, MCP-1、ET-1、ROCKⅠwere observed in the two groups before and after two weeks of treatment. Student t-test was applied to compare the difference of pre- and post-treatment hs-CRP、MCP-1、ET-1 and ROCKⅠlevels within and between pre- and post-treatment, Chi-square was applied to compare the difference between groups.

Improvement of clinical symptoms: the total effective rate of fasudil group was 87.80%, higher than of control group of 65.85% (χ²=68.176, P < 0.05). Improvement of ECG: the total effective rate of fasudil group was 82.92%, higher than of control group of 58.84% (χ²=60.463, P < 0.05). TIMI improved significantly in the two group post- treatment compared with pre- treatment with t values of (t=4.376, 0.353 and P < 0.05, 0.01). TIMI improved significantly in the fasudil group after treatment compared with conventional therapy group after treatment with t values of 5.236 (P < 0.01). The peripheral blood levels of hs-CRP, MCP-1、ET-1、ROCK Ⅰin fasudil treatment group were significantly reduced compared with pre- treatment (t=6.049, 5.294, 5.662, 6.191 and P < 0.05 or 0.01). The pre- treatment hs-CRP, MCP-1, ET-1, ROCK I levels in fasudil treatment group were significantly reduced compared with conventional therapy group (t=3.958, 4.496, 4.363, 3.875 and P < 0.01).

Fasudil can inhibit the inflammatory cytokines and improve the endothelial function, to improve curative effect of coronary slow flow.